US20060177502A1 - Sustained release pharmaceutical formulations - Google Patents
Sustained release pharmaceutical formulations Download PDFInfo
- Publication number
- US20060177502A1 US20060177502A1 US11/326,965 US32696506A US2006177502A1 US 20060177502 A1 US20060177502 A1 US 20060177502A1 US 32696506 A US32696506 A US 32696506A US 2006177502 A1 US2006177502 A1 US 2006177502A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- ranolazine
- magnesium stearate
- angina
- hydroxypropyl methylcellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/326,965 US20060177502A1 (en) | 2005-01-06 | 2006-01-05 | Sustained release pharmaceutical formulations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64216805P | 2005-01-06 | 2005-01-06 | |
US11/326,965 US20060177502A1 (en) | 2005-01-06 | 2006-01-05 | Sustained release pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060177502A1 true US20060177502A1 (en) | 2006-08-10 |
Family
ID=36648222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/326,965 Abandoned US20060177502A1 (en) | 2005-01-06 | 2006-01-05 | Sustained release pharmaceutical formulations |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060177502A1 (fr) |
EP (1) | EP1841411A2 (fr) |
JP (1) | JP2008526879A (fr) |
KR (1) | KR20070093988A (fr) |
CN (1) | CN101098682A (fr) |
AU (1) | AU2006203890A1 (fr) |
BR (1) | BRPI0606403A2 (fr) |
CA (1) | CA2593593A1 (fr) |
GE (1) | GEP20094784B (fr) |
IL (1) | IL184460A0 (fr) |
MX (1) | MX2007008162A (fr) |
NO (1) | NO20074037L (fr) |
RU (1) | RU2384332C2 (fr) |
UA (1) | UA90875C2 (fr) |
WO (1) | WO2006074398A2 (fr) |
ZA (1) | ZA200705530B (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080009503A1 (en) * | 2002-05-21 | 2008-01-10 | Andrew Wolff | Method of treating diabetes |
US20080193530A1 (en) * | 2007-02-13 | 2008-08-14 | Brent Blackburn | Use of ranolazine for the treatment of non-coronary microvascular diseases |
US20080214555A1 (en) * | 2007-02-13 | 2008-09-04 | Markus Jerling | Use of ranolazine for the treatment of cardiovascular diseases |
US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
US20080248112A1 (en) * | 2007-02-13 | 2008-10-09 | Brent Blackburn | Use of ranolazine for the treatment of coronary microvascular diseases |
US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
US20090203707A1 (en) * | 2008-02-06 | 2009-08-13 | Sridharan Rajamani | Methods for treating pain |
US20100197701A1 (en) * | 2002-05-21 | 2010-08-05 | Gilead Palo Alto, Inc. | Method of treating diabetes |
US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
WO2010137040A2 (fr) | 2009-05-28 | 2010-12-02 | Lupin Limited | Nouvelles compositions pharmaceutiques de ranolazine |
WO2011036677A2 (fr) | 2009-09-25 | 2011-03-31 | Lupin Limited | Composition de ranolazine à libération prolongée |
WO2011084733A1 (fr) | 2009-12-21 | 2011-07-14 | Gilead Sciences, Inc. | Méthode de traitement de la fibrillation atriale |
WO2011159706A1 (fr) | 2010-06-16 | 2011-12-22 | Gilead Sciences, Inc. | Ranolazine destinée à être utilisée pour le traitement de l'hypertension pulmonaire |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2139480A1 (fr) * | 2007-04-12 | 2010-01-06 | CV Therapeutics Inc. | Ranolazine utilisée pour améliorer la sécrétion d'insuline |
BRPI0721741A2 (pt) * | 2007-05-31 | 2013-02-13 | Cv Therapeutics Inc | mÉtodo de tratamento de diabetes |
CN101066253B (zh) * | 2007-06-07 | 2011-01-05 | 北京本草天源药物研究院 | 一种雷诺嗪缓释片 |
ES2414384T3 (es) | 2011-05-11 | 2013-07-19 | Ratiopharm Gmbh | Composición de liberación modificada que comprende ranolazina |
CN104758265B (zh) * | 2014-01-07 | 2019-05-17 | 四川海思科制药有限公司 | 一种雷诺嗪缓释片药物组合物及其制备方法 |
WO2016144855A1 (fr) * | 2015-03-07 | 2016-09-15 | Innophos, Inc. | Composition de levage pour remplacer des acides de levage à base d'aluminium |
TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
WO2018001582A1 (fr) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Comprimés multiples à base de ranolazine |
CN110859843A (zh) * | 2019-12-17 | 2020-03-06 | 卓和药业集团有限公司 | 一种治疗动脉硬化合并心绞痛的药物组合物及制备方法 |
CN111000818A (zh) * | 2020-01-04 | 2020-04-14 | 东莞市东阳光仿制药研发有限公司 | 一种雷诺嗪组合物及其制备方法 |
GR1010345B (el) * | 2021-12-16 | 2022-11-28 | Φαρματεν Α.Β.Ε.Ε., | Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
US5403593A (en) * | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
US5472707A (en) * | 1993-05-13 | 1995-12-05 | Syntex (U.S.A.) Inc. | High dose ranolazine formulations |
US5506229A (en) * | 1989-06-23 | 1996-04-09 | Syntex Pharmaceuticals, Ltd. | Methods of treatment using ranolazine and related piperazine derivatives |
US5670171A (en) * | 1989-09-18 | 1997-09-23 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
US20040063717A1 (en) * | 2002-05-21 | 2004-04-01 | Andrew Wolff | Method of treating diabetes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6242918A (ja) * | 1985-08-20 | 1987-02-24 | Kaken Pharmaceut Co Ltd | 持続性製剤 |
AU622254B2 (en) * | 1989-01-03 | 1992-04-02 | Sterling Drug Inc. | Controlled-release, low dose aspirin |
US6083532A (en) * | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
-
2006
- 2006-01-05 JP JP2007550511A patent/JP2008526879A/ja active Pending
- 2006-01-05 WO PCT/US2006/000503 patent/WO2006074398A2/fr active Application Filing
- 2006-01-05 EP EP06717674A patent/EP1841411A2/fr not_active Withdrawn
- 2006-01-05 GE GEAP200610166A patent/GEP20094784B/en unknown
- 2006-01-05 RU RU2007125656/15A patent/RU2384332C2/ru not_active IP Right Cessation
- 2006-01-05 UA UAA200707605A patent/UA90875C2/ru unknown
- 2006-01-05 BR BRPI0606403-5A patent/BRPI0606403A2/pt not_active IP Right Cessation
- 2006-01-05 MX MX2007008162A patent/MX2007008162A/es unknown
- 2006-01-05 KR KR1020077015511A patent/KR20070093988A/ko not_active Application Discontinuation
- 2006-01-05 US US11/326,965 patent/US20060177502A1/en not_active Abandoned
- 2006-01-05 AU AU2006203890A patent/AU2006203890A1/en not_active Abandoned
- 2006-01-05 CN CNA2006800018333A patent/CN101098682A/zh active Pending
- 2006-01-05 CA CA002593593A patent/CA2593593A1/fr not_active Abandoned
-
2007
- 2007-07-05 IL IL184460A patent/IL184460A0/en unknown
- 2007-07-06 ZA ZA200705530A patent/ZA200705530B/xx unknown
- 2007-08-03 NO NO20074037A patent/NO20074037L/no not_active Application Discontinuation
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
US5506229A (en) * | 1989-06-23 | 1996-04-09 | Syntex Pharmaceuticals, Ltd. | Methods of treatment using ranolazine and related piperazine derivatives |
US5906988A (en) * | 1989-06-23 | 1999-05-25 | Syntex (U.S.A.) Inc. | Methods of treatment using ranolazine and related piperazine derivatives |
US5670171A (en) * | 1989-09-18 | 1997-09-23 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
US5403593A (en) * | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
US5472707A (en) * | 1993-05-13 | 1995-12-05 | Syntex (U.S.A.) Inc. | High dose ranolazine formulations |
US6369062B1 (en) * | 1998-09-10 | 2002-04-09 | Cv Therapeutics, Inc. | Sustained release ranolazine formulations |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6503911B2 (en) * | 1998-09-10 | 2003-01-07 | Cv Therapeutics, Inc. | Sustained release ranolazine formulations |
US6525057B2 (en) * | 1998-09-10 | 2003-02-25 | Cv Therapeutics, Inc. | Sustained release ranolazine formulations |
US6562826B1 (en) * | 1998-09-10 | 2003-05-13 | Cv Therapeutics, Inc. | Sustained release ranolazine formulations |
US6617328B2 (en) * | 1998-09-10 | 2003-09-09 | Cv Therapeutics, Inc | Sustained release ranolazine formulations |
US6852724B2 (en) * | 1998-09-10 | 2005-02-08 | Cv Therapeutics, Inc. | Sustained release ranolazine formulations |
US6864258B2 (en) * | 1998-09-10 | 2005-03-08 | Andrew A. Wolff | Sustained release ranolazine formulations |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
US20040063717A1 (en) * | 2002-05-21 | 2004-04-01 | Andrew Wolff | Method of treating diabetes |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080009503A1 (en) * | 2002-05-21 | 2008-01-10 | Andrew Wolff | Method of treating diabetes |
US8883750B2 (en) | 2002-05-21 | 2014-11-11 | Gilead Sciences, Inc. | Method of treating diabetes |
US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
US8314104B2 (en) | 2002-05-21 | 2012-11-20 | Gilead Sciences, Inc. | Method of treating diabetes |
US20100197701A1 (en) * | 2002-05-21 | 2010-08-05 | Gilead Palo Alto, Inc. | Method of treating diabetes |
EP2216024A2 (fr) | 2007-02-13 | 2010-08-11 | Cv Therapeutics, Inc. | Utilisation de ranolazine pour le traitement de maladies cardiovasculaires |
US20080193530A1 (en) * | 2007-02-13 | 2008-08-14 | Brent Blackburn | Use of ranolazine for the treatment of non-coronary microvascular diseases |
US20080214555A1 (en) * | 2007-02-13 | 2008-09-04 | Markus Jerling | Use of ranolazine for the treatment of cardiovascular diseases |
US20080214556A1 (en) * | 2007-02-13 | 2008-09-04 | Markus Jerling | Use of ranolazine for the treatment of cardiovascular diseases |
US20080248112A1 (en) * | 2007-02-13 | 2008-10-09 | Brent Blackburn | Use of ranolazine for the treatment of coronary microvascular diseases |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
US20100197684A1 (en) * | 2007-07-05 | 2010-08-05 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
US9045428B2 (en) | 2007-07-05 | 2015-06-02 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US8716319B2 (en) | 2007-07-05 | 2014-05-06 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
US20090203707A1 (en) * | 2008-02-06 | 2009-08-13 | Sridharan Rajamani | Methods for treating pain |
US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
US8901128B2 (en) | 2009-05-28 | 2014-12-02 | Lupin Limited | Pharmaceutical compositions of ranolazine |
WO2010137040A2 (fr) | 2009-05-28 | 2010-12-02 | Lupin Limited | Nouvelles compositions pharmaceutiques de ranolazine |
EP2515880B1 (fr) * | 2009-05-28 | 2019-11-27 | Lupin Limited | Nouvelles compositions pharmaceutiques de ranolazine |
US20120177729A1 (en) * | 2009-09-25 | 2012-07-12 | Lupin Limited | Sustained release composition of ranolazine |
WO2011036677A2 (fr) | 2009-09-25 | 2011-03-31 | Lupin Limited | Composition de ranolazine à libération prolongée |
WO2011084733A1 (fr) | 2009-12-21 | 2011-07-14 | Gilead Sciences, Inc. | Méthode de traitement de la fibrillation atriale |
EP2749282A1 (fr) | 2009-12-21 | 2014-07-02 | Gilead Sciences, Inc. | Méthode de traitement de la fibrillation auriculaire |
WO2011159706A1 (fr) | 2010-06-16 | 2011-12-22 | Gilead Sciences, Inc. | Ranolazine destinée à être utilisée pour le traitement de l'hypertension pulmonaire |
Also Published As
Publication number | Publication date |
---|---|
WO2006074398A2 (fr) | 2006-07-13 |
JP2008526879A (ja) | 2008-07-24 |
UA90875C2 (ru) | 2010-06-10 |
IL184460A0 (en) | 2007-10-31 |
NO20074037L (no) | 2007-08-03 |
WO2006074398A3 (fr) | 2007-02-22 |
AU2006203890A1 (en) | 2006-07-13 |
CA2593593A1 (fr) | 2006-07-13 |
ZA200705530B (en) | 2008-10-29 |
KR20070093988A (ko) | 2007-09-19 |
CN101098682A (zh) | 2008-01-02 |
RU2384332C2 (ru) | 2010-03-20 |
BRPI0606403A2 (pt) | 2009-06-23 |
GEP20094784B (en) | 2009-09-25 |
EP1841411A2 (fr) | 2007-10-10 |
MX2007008162A (es) | 2007-07-24 |
RU2007125656A (ru) | 2009-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060177502A1 (en) | Sustained release pharmaceutical formulations | |
JP5641682B2 (ja) | 徐放性ナノ粒子組成物 | |
AU2005271192B2 (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof | |
AU2001240092B8 (en) | Sustained release ranolazine formulations | |
JP2916152B2 (ja) | 薬物放出速度調節型製剤 | |
WO1999016448A1 (fr) | Comprime de theophylline a liberation prolongee | |
CN102348458A (zh) | 含有6-氟-3-羟基-2-吡嗪甲酰胺的片剂和粒状粉剂 | |
US8617601B2 (en) | Methods and formulations for making pharmaceutical compositions containing bupropion | |
WO2005013964A1 (fr) | Preparation pharmaceutique contenant du nateglinide | |
US20170202801A1 (en) | Stabilization Of Moisture-Sensitive Drugs | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
WO2006103551A1 (fr) | Formulations d’oxycodone a liberation controlee | |
MXPA04009701A (es) | Formulaciones de metoprolol de liberacion sostenida. | |
JP2010536798A (ja) | 難溶性薬物の生体利用率を制御するための方法及び組成物 | |
JP2009519313A (ja) | 医薬組成物 | |
US20070160667A1 (en) | Controlled release formulation of divalproex sodium | |
EP1815850B1 (fr) | Formulation à libération contrôlée comprenant acide valproique et ses dérivés | |
US20080260785A1 (en) | Paroxetine compositions | |
JP3007387B2 (ja) | 徐放性製剤用基剤粉末 | |
WO2008091870A2 (fr) | Compositions pharmaceutiques comprenant de l'atorvastatine et de l'acide nicotinique | |
JP2009538905A (ja) | 感湿性薬物を含んで成る安定性製剤及びその製造方法 | |
US20080182908A1 (en) | Pharmaceutical compositions comprising memantine | |
Syukri et al. | Formulation of Chlorpheniramine Maleate Tablets Using Co-Processed Excipient As A Filler And Binder | |
TW201609196A (zh) | 控制釋放製劑及其製備方法 | |
AGIBA et al. | Modulatory effect of polymer type and concentration on drug release from sustained release matrix tablets of ranolazine: a comparative release kinetic study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CV THERAPEUTICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SASTRY, SRIKONDA;NYSHADHAM, JANAKI;REEL/FRAME:017634/0852;SIGNING DATES FROM 20060418 TO 20060424 |
|
AS | Assignment |
Owner name: GILEAD PALO ALTO, INC., CALIFORNIA Free format text: MERGER;ASSIGNORS:APEX MERGER SUB, INC.;CV THERAPEUTICS, INC.;REEL/FRAME:024838/0650 Effective date: 20090417 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: GILEAD SCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GILEAD PALO ALTO, INC.;REEL/FRAME:026426/0553 Effective date: 20110511 |